SEC Comment Letter 0000000000-24-004928 to Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc.
Date: May 1, 2024 · CIK: 0001649989 · Accession: 0000000000-24-004928
AI Filing Summary & Sentiment
File numbers found in text: 333-278959
Letter
United States securities and exchange commission logo May 1, 2024 Lawrence A. Kenyon Chief Financial Officer Outlook Therapeutics, Inc. 485 Route 1 South Building F, Suite 320 Iselin, New Jersey 08830 Re:Outlook Therapeutics, Inc. Registration Statement on Form S-3 Filed April 26, 2024 File No. 333-278959 Dear Lawrence A. Kenyon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Courtney M.W. Tygesson
Show Raw Text
United States securities and exchange commission logo
May 1, 2024
Lawrence A. Kenyon
Chief Financial Officer
Outlook Therapeutics, Inc.
485 Route 1 South
Building F, Suite 320
Iselin, New Jersey 08830
Re:Outlook Therapeutics, Inc.
Registration Statement on Form S-3
Filed April 26, 2024
File No. 333-278959
Dear Lawrence A. Kenyon:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Courtney M.W. Tygesson